Pricing and Market Access of Orphan Drugs in Asia: a Comparative Study Across Growth Markets.

• With the majority of the world’s population, a large number of patients with rare diseases and relatively limited access to appropriate medicines compared with western countries, Asia represents a real opportunity for the commercialisation of orphan drugs • However, despite some countries implementing policy to facilitate this process, funding for orphan drugs remains challenging since healthcare budgets are primarily focused on essential medicines for the broader population • To understand the current coverage policies for orphan drugs in China, Taiwan, Singapore and South Korea • To evaluate the impact policy has on the pricing and reimbursement status of orphan drugs and to define the drivers for access, in light of an increasing pressure on medical coverage for orphan conditions